|
1
|
Vigneswaran N and Williams MD:
Epidemiologic trends in head and neck cancer and aids in diagnosis.
Oral Maxillofac Surg Clin North Am. 26:123–141. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Macmillan Cancer Support: Types of head
and neck cancer. https://www.macmillan.org.uk/information-and-support/head-and-neck-cancers/understanding-cancer/types-head-neck-cancer.htmlFeb.
2016
|
|
3
|
Hashibe M, Brennan P, Chuang SC, Boccia S,
Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova
E, et al: Interaction between tobacco and alcohol use and the risk
of head and neck cancer: Pooled analysis in the international head
and neck cancer epidemiology consortium. Cancer Epidemiol
Biomarkers Prev. 18:541–550. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fung C and Grandis JR: Emerging drugs to
treat squamous cell carcinomas of the head and neck. Expert Opin
Emerg Drugs. 15:355–373. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Adelstein D, Gillison ML, Pfister DG,
Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ,
Cmelak AJ, et al: NCCN Guidelines insights: Head and neck cancers,
version 2.2017. J Natl Compr Canc Netw. 15:761–770. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brierley JD, Gospodarowicz MK and
Wittekind CH: TNM Classification of Malignant Tumours Eighth
Edition. Chichester, West Sussex, UK; Hoboken, NJ: John Wiley &
Sons, Inc.; 2017
|
|
7
|
Pignon JP, le Maitre A, Maillard E and
Bourhis J: MACH-NC Collaborative Group: Meta-analysis of
chemotherapy in head and neck cancer (MACH-NC): An update on 93
randomised trials and 17,346 patients. Radiother Oncol. 92:4–14.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Argiris A, Karamouzis MV, Raben D and
Ferris RL: Head and neck cancer. Lancet. 371:1695–1709. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Suh Y, Amelio I, Urbano Guerrero T and
Tavassoli M: Clinical update on cancer: Molecular oncology of head
and neck cancer. Cell Death Dis. 5:e10182014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Boeckx C, Baay M, Wouters A, Specenier P,
Vermorken JB, Peeters M and Lardon F: Anti-epidermal growth factor
receptor therapy in head and neck squamous cell carcinoma: Focus on
potential molecular mechanisms of drug resistance. Oncologist.
18:850–864. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
National Cancer Institute: NCI Dictionary
of Cancer Terms: Definition of targeted therapy. https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=270742Feb.
2016
|
|
12
|
Goerner M, Seiwert TY and Sudhoff H:
Molecular targeted therapies in head and neck cancer-An update of
recent developments. Head Neck Oncol. 2:82010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Song J, Chen C and Raben D: Emerging role
of EGFR-Targeted therapies and radiation in head and neck cancer.
Oncology (Williston Park). 18(1757–1767): 1771–1772, 1777.
2004.
|
|
14
|
Lurje G and Lenz HJ: EGFR signaling and
drug discovery. Oncology. 77:400–410. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schwab M: Broder histological
classificationEncyclopedia of Cancer. Berlin Heidelberg: Springer;
2011, View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Alterio D, Marvaso G, Maffini F, Gandini
S, Chiocca S, Ferrari A, Preda L, Rocca MC, Lepanto D, Fodor C, et
al: Role of EGFR as prognostic factor in head and neck cancer
patients treated with surgery and postoperative radiotherapy:
Proposal of a new approach behind the EGFR overexpression. Med
Oncol. 34:1072017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Keren S, Shoude Z, Lu Z and Beibei Y: Role
of EGFR as a prognostic factor for survival in head and neck
cancer: A meta-analysis. Tumour Biol. 35:2285–2295. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Markovic A and Chung CH: Current role of
EGF receptor monoclonal antibodies and tyrosine kinase inhibitors
in the management of head and neck squamous cell carcinoma. Expert
Rev Anticancer Ther. 12:1149–1159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Obradović J, Djordjević N, Tošic N,
Mrdjanović J, Stanković B, Stanić J, Zarić B, Perin B, Pavlović S
and Jurišić V: Frequencies of EGFR single nucleotide polymorphisms
in non-small cell lung cancer patients and healthy individuals in
the Republic of Serbia: A preliminary study. Tumour Biol.
37:10479–10486. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Matta A and Ralhan R: Overview of current
and future biologically based targeted therapies in head and neck
squamous cell carcinoma. Head Neck Oncol. 1:62009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang SM and Harari PM: Modulation of
radiation response after epidermal growth factor receptor blockade
in squamous cell carcinomas: Inhibition of damage repair, cell
cycle kinetics, and tumor angiogenesis. Clin Cancer Res.
6:2166–2174. 2000.PubMed/NCBI
|
|
22
|
Cunningham D, Humblet Y, Siena S, Khayat
D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype
C, et al: Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl J Med.
351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vermorken JB, Mesia R, Rivera F, Remenar
E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol
D, et al: Platinum-based chemotherapy plus cetuximab in head and
neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan
PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar
AK, et al: Randomized phase III trial of concurrent accelerated
radiation plus cisplatin with or without cetuximab for stage III to
IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 32:2940–2950.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ang KK, Harris J, Wheeler R, Weber R,
Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C,
et al: Human papillomavirus and survival of patients with
oropharyngeal cancer. N Engl J Med. 363:24–35. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mirghani H, Amen F, Blanchard P, Moreau F,
Guigay J, Hartl DM and St Guily Lacau J: Treatment de-escalation in
HPV-positive oropharyngeal carcinoma: Ongoing trials, critical
issues and perspectives. Int J Cancer. 136:1494–1503. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Van Damme N, Deron P, Van Roy N, Demetter
P, Bols A, Van Dorpe J, Baert F, Van Laethem JL, Speleman F,
Pauwels P and Peeters M: Epidermal growth factor receptor and K-ras
status in two cohorts of squamous cell carcinomas. BMC Cancer.
10:1892010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Burtness B, Goldwasser MA, Flood W, Mattar
B and Forastiere AA: Eastern Cooperative Oncology Group: Phase III
randomized trial of cisplatin plus placebo compared with cisplatin
plus cetuximab in metastatic/recurrent head and neck cancer: An
eastern cooperative oncology group study. J Clin Oncol.
23:8646–8654. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bonner JA, Harari PM, Giralt J, Cohen RB,
Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, et al:
Radiotherapy plus cetuximab for locoregionally advanced head and
neck cancer: 5-year survival data from a phase 3 randomised trial,
and relation between cetuximab-induced rash and survival. Lancet
Oncol. 11:21–28. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Z, Martin D, Molinolo AA, Patel V,
Iglesias-Bartolome R, Degese MS, Vitale-Cross L, Chen Q and Gutkind
JS: mTOR co-targeting in cetuximab resistance in head and neck
cancers harboring PIK3CA and RAS mutations. J Natl Cancer Inst.
106:pii:dju2152014. View Article : Google Scholar
|
|
32
|
Boeckx C, de Beeck Op K, Wouters A,
Deschoolmeester V, Limame R, Zwaenepoel K, Specenier P, Pauwels P,
Vermorken JB, Peeters M, et al: Overcoming cetuximab resistance in
HNSCC: The role of AURKB and DUSP proteins. Cancer Lett.
354:365–377. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Knowles LM, Stabile LP, Egloff AM,
Rothstein ME, Thomas SM, Gubish CT, Lerner EC, Seethala RR, Suzuki
S, Quesnelle KM, et al: HGF and c-Met participate in paracrine
tumorigenic pathways in head and neck squamous cell cancer. Clin
Cancer Res. 15:3740–3750. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vermorken JB, Stöhlmacher-Williams J,
Davidenko I, Licitra L, Winquist E, Villanueva C, Foa P, Rottey S,
Skladowski K, Tahara M, et al: Cisplatin and fluorouracil with or
without panitumumab in patients with recurrent or metastatic
squamous-cell carcinoma of the head and neck (SPECTRUM): An
open-label phase 3 randomised trial. Lancet Oncol. 14:697–710.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Eriksen JG, Maare C, Johansen J, Primdahl
H, Evensen J, Kristensen CA, Andersen LJ and Overgaard J:
DAHANCA19: A randomized phase III study of primary (chemo-)
radiotherapy and zalutumumab in head and neck carcinomas. ESTRO 33
Congress Report. 112014.
|
|
36
|
Sundaram S, Venkatanarayan B, Sridharan N
and Poojar K: Nimotuzumab with induction chemotherapy and
chemo-radiation in patients with advanced head and neck cancer. J
Cancer Ther. 6:146–152. 2015. View Article : Google Scholar
|
|
37
|
ClinicalTrials.gov, . NCT02012062 phase
III study of neoadjuvant TPF chemotherapy followed by radiotherapy
and concurrent nimotuzumab or cisplatin for locoregionally advanced
nasopharyngeal carcinoma (NPC). https://clinicaltrials.gov/ct2/show/NCT02012062Sept.
2015
|
|
38
|
Chapman CH, Saba NF and Yom SS: Targeting
epidermal growth factor receptor for head and neck squamous cell
carcinoma: Still lost in translation? Ann Transl Med.
4:802016.PubMed/NCBI
|
|
39
|
Kit OI, Vodolazhsky DI, Timoshkina NN,
Vladimirova LY, Turkin IN, Kutsyn KA, Enin YS, Panina SB and
Jurisic V: EGFR mutations and tumor metastases in patients with
nonsmall cell lung cancer in the South οf Russia. J BUON.
22:1410–1415. 2017.PubMed/NCBI
|
|
40
|
Loeffler-Ragg J, Witsch-Baumgartner M,
Tzankov A, Hilbe W, Schwentner I, Sprinzl GM, Utermann G and
Zwierzina H: Low incidence of mutations in EGFR kinase domain in
Caucasian patients with head and neck squamous cell carcinoma. Eur
J Cancer. 42:109–111. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Martins RG, Parvathaneni U, Bauman JE,
Sharma AK, Raez LE, Papagikos MA, Yunus F, Kurland BF, Eaton KD,
Liao JJ, et al: Cisplatin and radiotherapy with or without
erlotinib in locally advanced squamous cell carcinoma of the head
and neck: A randomized phase II trial. J Clin Oncol. 31:1415–1421.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fumagalli I, Dugue D, Bibault JE,
Clémenson C, Vozenin MC, Mondini M and Deutsch E: Cytotoxic effect
of lapatinib is restricted to human papillomavirus-positive head
and neck squamous cell carcinoma cell lines. Onco Targets Ther.
8:335–345. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Harrington K, Berrier A, Robinson M,
Remenar E, Housset M, de Mendoza FH, Fayette J, Mehanna H,
El-Hariry I, Compton N, et al: Randomised Phase II study of oral
lapatinib combined with chemoradiotherapy in patients with advanced
squamous cell carcinoma of the head and neck: Rationale for future
randomised trials in human papilloma virus-negative disease. Eur J
Cancer. 49:1609–1618. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Weiss JM, Bagley S, Hwang WT, Bauml J,
Olson JG, Cohen RB, Hayes DN and Langer C: Capecitabine and
lapatinib for the first-line treatment of metastatic/recurrent head
and neck squamous cell carcinoma. Cancer. 122:2350–2355. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Modjtahedi H, Cho BC, Michel MC and Solca
F: A comprehensive review of the preclinical efficacy profile of
the ErbB family blocker afatinib in cancer. Naunyn Schmiedebergs
Arch Pharmacol. 387:505–521. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sequist LV, Yang JC, Yamamoto N, O'Byrne
K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, et al:
Phase III study of afatinib or cisplatin plus pemetrexed in
patients with metastatic lung adenocarcinoma with EGFR mutations. J
Clin Oncol. 31:3327–3334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Seiwert TY, Fayette J, Cupissol D, Del
Campo JM, Clement PM, Hitt R, Degardin M, Zhang W, Blackman A,
Ehrnrooth E and Cohen EE: A randomized, phase II study of afatinib
versus cetuximab in metastatic or recurrent squamous cell carcinoma
of the head and neck. Ann Oncol. 25:1813–1820. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Burtness B, Bourhis JP, Vermorken JB,
Harrington KJ and Cohen EE: Afatinib versus placebo as adjuvant
therapy after chemoradiation in a double-blind, phase III study
(LUX-Head & Neck 2) in patients with primary unresected,
clinically intermediate-to-high-risk head and neck cancer: Study
protocol for a randomized controlled trial. Trials. 15:4692014.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Razak Abdul AR, Soulières D, Laurie SA,
Hotte SJ, Singh S, Winquist E, Chia S, Le Tourneau C, Nguyen-Tan
PF, Chen EX, et al: A phase II trial of dacomitinib, an oral
pan-human EGF receptor (HER) inhibitor, as first-line treatment in
recurrent and/or metastatic squamous-cell carcinoma of the head and
neck. Ann Oncol. 24:761–769. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hinerman RW, Mendenhall WM, Morris CG,
Amdur RJ, Werning JW and Villaret DB: Postoperative irradiation for
squamous cell carcinoma of the oral cavity: 35 year experience.
Head Neck. 26:984–994. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Minchenko A, Bauer T, Salceda S and Caro
J: Hypoxic stimulation of vascular endothelial growth factor
expression in vitro and in vivo. Lab Invest. 3:374–379. 1994.
|
|
52
|
Kyzas PA, Cunha IW and Ioannidis JP:
Prognostic significance of vascular endothelial growth factor
immunohistochemical expression in head and neck squamous cell
carcinoma: A meta-analysis. Clin Cancer Res. 11:1434–1440. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Chen Z and Xu XH: Combining antiangiogenic
therapy and radiation in nasopharyngeal carcinoma. Saudi Med J.
36:659–664. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Vokes EE, Cohen EEW, Mauer AM, Karrison
TG, Wong SJ, Skoog-Sluman LJ, Kozloff MF, Dancey J and Dekker A: A
phase I study of erlotinib and bevacizumab for recurrent or
metastatic squamous cell carcinoma of the head and neck (HNC). J
Clin Oncol. 23 Suppl 16:S55042005. View Article : Google Scholar
|
|
55
|
Burtness B: Commentary Bevacizumab and
erlotinib with chemoradiation for head and neck cancer. Cancer J.
17:273–275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Cohen EE, Davis DW, Karrison TG, Seiwert
TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, et al:
Erlotinib and bevacizumab in patients with recurrent or metastatic
squamous-cell carcinoma of the head and neck: A phase I/II study.
Lancet Oncol. 3:247–257. 2009. View Article : Google Scholar
|
|
57
|
Feinstein T, Raez L, Rajasenan K, Gibson
MK, Savvides P, Karamouzis MV, Garg N, Johnson R, Branstetter BF
and Argiris AE: Pemetrexed (P) and bevacizumab (B) in patients
(pts) with recurrent or metastatic head and neck squamous cell
carcinoma (HNSCC): Updated results of a Phase II trial. J Clin
Oncol. 26 15 Suppl:S60692008. View Article : Google Scholar
|
|
58
|
Argiris A, Kotsakis AP, Hoang T, Worden
FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR Jr, Chen
HX, Grandis JR, et al: Cetuximab and bevacizumab: Preclinical data
and phase II trial in recurrent or metastatic squamous cell
carcinoma of the head and neck. Ann Oncol. 24:220–225. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Fury MG, Lee NY, Sherman E, Lisa D, Kelly
K, Lipson B, Carlson D, Stambuk H, Haque S, Shen R, et al: A phase
2 study of bevacizumab with cisplatin plus intensity-modulated
radiation therapy for stage III/IVB head and neck squamous cell
cancer. Cancer. 15:5008–5014. 2012. View Article : Google Scholar
|
|
60
|
ClinicalTrials.gov, . NCT00968435
Bevacizumab, Cetuximab, and cisplatin with IMRT
(Intensity-Modulated Radiation Therapy) for patients with stage
III/IV head and neck squamous cell carcinoma. https://clinicaltrials.gov/ct2/show/NCT00968435/Jun.
2016
|
|
61
|
Zhang Y, Xue D, Wang X, Lu M, Gao B and
Qiao X: Screening of kinase inhibitors targeting BRAF for
regulating autophagy based on kinase pathways. Mol Med Rep.
9:83–90. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yadav A, Kumar B, Teknos TN and Kumar P:
Sorafenib enhances the antitumor effects of chemoradiation
treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins.
Mol Cancer Ther. 10:1241–1251. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Möckelmann N, Rieckmann T, Busch CJ,
Becker B, Gleissner L, Hoffer K, Omniczynski M, Steinmeister L,
Laban S, Grénman R, et al: Effect of sorafenib on cisplatin-based
chemoradiation in head and neck cancer cells. Oncotarget.
7:23542–23551. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Laban S, Steinmeister L, Gleissner L, Grob
TJ, Grénman R, Petersen C, Gal A, Knecht R, Dikomey E and Kriegs M:
Sorafenib sensitizes head and neck squamous cell carcinoma cells to
ionizing radiation. Radiother Oncol. 109:286–292. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Bozec A, Sudaka A, Toussan N, Fischel JL,
Etienne-Grimaldi MC and Milano G: Combination of sunitinib,
cetuximab and irradiation in an orthotopic head and neck cancer
model. Ann Oncol. 20:1703–1707. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Machiels JP, Henry S, Zanetta S, Kaminsky
MC, Michoux N, Rommel D, Schmitz S, Bompas E, Dillies AF, Faivre S,
et al: Phase II study of sunitinib in recurrent or metastatic
squamous cell carcinoma of the head and neck: GORTEC 2006–01. J
Clin Oncol. 28:21–28. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Heymach JV, Johnson BE, Prager D, Csada E,
Roubec J, Pesek M, Spásová I, Belani CP, Bodrogi I, Gadgeel S, et
al: Randomized, placebo-controlled phase II study of vandetanib
plus docetaxel in previously treated non small-cell lung cancer. J
Clin Oncol. 25:4270–4277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Papadimitrakopoulou VA, Frank SJ, Cohen
EW, Hirsch FR, Myers JN, Heymach JV, Lin H, Tran HT, Chen CR,
Jimeno A, et al: Phase I study of vandetanib with radiation therapy
with or without cisplatin in locally advanced head and neck
squamous cell carcinoma. Head Neck. 38:439–447. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Hsu HW, Wall NR, Hsueh CT, Kim S, Ferris
RL, Chen CS and Mirshahidi S: Combination antiangiogenic therapy
and radiation in head and neck cancers. Oral Oncol. 50:19–26. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Brands RC, Knierim LM, De Donno F,
Steinacker V, Hartmann S, Seher A, Kübler AC and Müller-Richter UD:
Targeting VEGFR and FGFR in head and neck squamous cell carcinoma
in vitro. Oncol Rep. 38:1877–1885. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Swiecicki PL, Zhao L, Belile E, Sacco AG,
Chepeha DB, Dobrosotskaya I, Spector M, Shuman A, Malloy K, Moyer
J, et al: A phase II study evaluating axitinib in patients with
unresectable, recurrent or metastatic head and neck cancer. Invest
New Drugs. 33:1248–1256. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Hsu HW, de Necochea-Campion R, Williams V,
Duerksen-Hughes PJ, Simental AA Jr, Ferris RL, Chen CS and
Mirshahidi S: Linifanib (ABT-869), enhances cytotoxicity with poly
(ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and
neck carcinoma cells. Oral Oncol. 50:662–669. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Kramer B, Hock C, Birk R, Sauter A, Stuck
BA, Hörmann K, Schultz JD and Aderhold C: Targeted therapies in
HPV-positive and -negative HNSCC-Alteration of EGFR and VEGFR-2
expression in vitro. Anticancer Res. 36:2799–2807. 2016.PubMed/NCBI
|
|
74
|
LoPiccolo J, Blumenthal GM, Bernstein WB
and Dennis PA: Targeting the PI3K/Akt/mTOR pathway: Effective
combinations and clinical considerations. Drug Resist Updat.
11:32–50. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Liu P, Cheng H, Roberts TM and Zhao JJ:
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev
Drug Discov. 8:627–644. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Lionello M, Blandamura S, Loreggian L,
Ottaviano G, Giacomelli L, Marchese-Ragona R, Velardita C,
Staffieri A and Marioni G: High mTOR expression is associated with
a worse oncological outcome in laryngeal carcinoma treated with
postoperative radiotherapy: A pilot study. J Oral Pathol Med.
41:136–140. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Zaytseva YY, Valentino JD, Gulhati P and
Evers BM: mTOR inhibitors in cancer therapy. Cancer Lett. 319:1–7.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Schedel F, Pries R, Thode B, Wollmann B,
Wulff S, Jocham D, Wollenberg B and Kausch I: mTOR inhibitors show
promising in vitro activity in bladder cancer and head and neck
squamous cell carcinoma. Oncol Rep. 25:763–768. 2011.PubMed/NCBI
|
|
79
|
Nathan CO, Amirghahari N, Rong X, Giordano
T, Sibley D, Nordberg M, Glass J, Agarwal A and Caldito G:
Mammalian target of rapamycin inhibitors as possible adjuvant
therapy for microscopic residual disease in head and neck squamous
cell cancer. Cancer Res. 67:2160–2168. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Bauman JE, Arias-Pulido H, Lee SJ,
Fekrazad MH, Ozawa H, Fertig E, Howard J, Bishop J, Wang H, Olson
GT, et al: A phase II study of temsirolimus and erlotinib in
patients with recurrent and/or metastatic, platinum-refractory head
and neck squamous cell carcinoma. Oral Oncol. 49:461–467. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Niehr F, Weichert W, Stenzinger A, Budach
V and Tinhofer I: CCI-779 (Temsirolimus) exhibits increased
antitumor activity in low EGFR expressing HNSCC cell lines and is
effective in cells with acquired resistance to cisplatin or
cetuximab. J Transl Med. 13:1062015. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Hollebecque A, Bahleda R, Faivre L, Adam
J, Poinsignon V, Paci A, Gomez-Roca C, Thery JC, Le Deley MC, Varga
A, et al: Phase I study of temsirolimus in combination with
cetuximab in patients with advanced solid tumors. Eur J Cancer.
81:81–89. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Li SH, Lin WC, Huang TL, Chen CH, Chiu TJ,
Fang FM, Huang WT, Hsu CM, Luo SD, Lai CC, et al: Significance of
mammalian target of rapamycin in patients with locally advanced
stage IV head and neck squamous cell carcinoma receiving induction
chemotherapy with docetaxel, cisplatin, and fluorouracil. Head
Neck. 38 Suppl 1:E844–E852. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
ClinicalTrials.gov, . NCT01016769
temsirolimus + weekly paclitaxel + carboplatin for recurrent or
metastatic head and neck squamous cell cancer (HNSCC). https://clinicaltrials.gov/ct2/show/NCT01016769Feb.
2016
|
|
85
|
ClinicalTrials.gov, . Everolimus versus
placebo in head and neck cancer. https://clinicaltrials.gov/ct2/show/NCT0111105820–Feb.
2016
|
|
86
|
Grzywnowicz M and Giannopoulos K: The role
of receptor programmed death-1 and its ligands in immune system and
tumors. Acta Haematol Pol. 43:132–145. 2012. View Article : Google Scholar
|
|
87
|
Dong H, Zhu G, Tamada K and Chen L: B7-H1,
a third member of the B7 family, co-stimulates T-cell proliferation
and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Hamid O, Robert C, Daud A, Hodi FS, Hwu
WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al:
Safety and tumor responses with lambrolizumab (anti-PD-1) in
melanoma. N Engl J Med. 2369:134–144. 2013. View Article : Google Scholar
|
|
89
|
Mehra R, Seiwert TY, Mahipal A, Weiss J,
Berger R, Eder JP, Burtness B, Tahara M, Keam B, Dung LE, et al:
Efficacy and safety of pembrolizumab in recurrent/metastatic head
and neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after
long-term follow-up in KEYNOTE-012. J Clin Oncol. 34 Suppl
15:S60122016.
|
|
90
|
ClinicalTrials.gov, . NCT02358031 a study
of pembrolizumab (MK-3475) for first line treatment of recurrent or
metastatic squamous cell cancer of the head and neck
(MK-3475-048/KEYNOTE-048). https://clinicaltrials.gov/ct2/show/NCT02358031Jun.
2016
|
|
91
|
Ferris RL, Blumenschein GR, Fayette J,
Guigay J, Colevas D, Licitra L, Harrington K, Kasper S, Vokes EE,
Even C, et al: Further evaluations of nivolumab (nivo) versus
investigator's choice (IC) chemotherapy for recurrent or metastatic
(R/M) squamous cell carcinoma of the head and neck (SCCHN):
CheckMate 141. J Clin Oncol. 34 Suppl 15:S60092016.
|
|
92
|
Ferris RL, Blumenschein GR, Fayette J,
Guigay J, Colevas D, Licitra L, Harrington K, Kasper S, Vokes EE,
Even C, et al: Nivolumab for recurrent Squamous-cell carcinoma of
the head and neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Seki T, Yun J and Oh SP: Arterial
endothelium-specifıc activin receptor-likekinase 1 expression
suggests its role in arterialization and vascular remodeling. Circ
Res. 93:682–689. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Cunha SI and Pietras K: ALK1 as an
emerging target for antiangiogenic therapy of cancer. Blood.
117:6999–7006. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Clinical Trials.gov, . NCT01458392 Study
of Dalantercept in Patients with squamous cell carcinoma of the
head and neck. https://clinicaltrials.gov/ct2/show/NCT01458392Jun.
2016
|
|
96
|
Hawinkels LJ, de Vinuesa AG, Paauwe M,
Kruithof-de Julio M, Wiercinska E, Pardali E, Mezzanotte L,
Keereweer S, Braumuller TM, Heijkants RC, et al: Activin
Receptor-like kinase 1 ligand trap reduces microvascular density
and improves chemotherapy efficiency to various solid tumors. Clin
Cancer Res. 22:96–106. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ,
Pandey ON, Franklin M, Kratzke RA, Greeno EW and Kumar P: Phase I
study of bortezomib and cetuximab in patients with solid tumours
expressing epidermal growth factor receptor. Br J Cancer.
100:1379–1384. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Chung CH, Aulino J, Muldowney NJ,
Hatakeyama H, Baumann J, Burkey B, Netterville J, Sinard R,
Yarbrough WG, Cmelak AJ, et al: Nuclear factor-kappa B pathway and
response in bortezomib and docetaxel in patients with recurrent
and/or metastatic head and neck squamous cell carcinoma. Ann Oncol.
21:864–870. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Argiris A, Duffy AG, Kummar S, Simone NL,
Arai Y, Kim SW, Rudy SF, Kannabiran VR, Yang X, Jang M, et al:
Early tumor progression associated with enhanced EGFR signaling
with bortezomib, cetuximab and radiotherapy for head and neck
cancer. Clin Cancer Res. 17:5755–5764. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Agrawal N, Frederick MJ, Pickering CR,
Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, et
al: Exome sequencing of head and neck squamous cell carcinoma
reveals inactivating mutations in NOTCH1. Science. 333:1154–1157.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Sun W, Gaykalova DA, Ochs MF, Mambo E,
Arnaoutakis D, Liu Y, Loyo M, Agrawal N, Howard J, Li R, et al:
Activation of the NOTCH pathway in Head and Neck cancer. Cancer
Res. 74:1091–1104. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Platonova N, Lesma E, Basile A, Bignotto
M, Garavelli S, Palano MT, Moschini A, Neri A, Colombo M and
Chiaramonte R: Targeting Notch as a therapeutic approach for human
malignancies. Curr Pharm Des. 23:108–134. 2017.PubMed/NCBI
|
|
103
|
Platonova N, Parravicini C, Sensi C, Paoli
A, Colombo M, Neri A, Eberini I and Chiaramonte R: Identification
of small molecules uncoupling the Notch: Jagged interaction through
an integrated high-throughput screening. PLoS One. 12:e01826402017.
View Article : Google Scholar : PubMed/NCBI
|
